Larroque-Lombard AL - Search Results

1

A bioanalytical investigation on the exquisitely strong in vitro potency of the EGFR-DNA targeting type II combi-molecule ZR2003 and its mitigated in vivo antitumour activity.

Golabi N, Brahimi F, Huang Y, Rachid Z, Qiu Q, Larroque-Lombard AL, Jean-Claude BJ. Golabi N, et al. Among authors: larroque lombard al. J Pharm Biomed Anal. 2011 Nov 1;56(3):592-9. doi: 10.1016/j.jpba.2011.06.013. Epub 2011 Jun 24. J Pharm Biomed Anal. 2011. PMID: 21764236

2

Synthesis and uptake of fluorescence-labeled Combi-molecules by P-glycoprotein-proficient and -deficient uterine sarcoma cells MES-SA and MES-SA/DX5.

Larroque-Lombard AL, Todorova M, Golabi N, Williams C, Jean-Claude BJ. Larroque-Lombard AL, et al. J Med Chem. 2010 Mar 11;53(5):2104-13. doi: 10.1021/jm9016043. J Med Chem. 2010. PMID: 20151639

3

Synthesis and studies on three-compartment flavone-containing combi-molecules designed to target EGFR, DNA, and MEK.

Larroque-Lombard AL, Todorova M, Qiyu Q, Jean-Claude B. Larroque-Lombard AL, et al. Chem Biol Drug Des. 2011 May;77(5):309-18. doi: 10.1111/j.1747-0285.2011.01098.x. Epub 2011 Mar 25. Chem Biol Drug Des. 2011. PMID: 21294849

4

"Combi-targeting" mitozolomide: conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer.

Fang Y, Qiu Q, Domarkas J, Larroque-Lombard AL, Rao S, Rachid Z, Gibbs BF, Gao X, Jean-Claude BJ. Fang Y, et al. Among authors: larroque lombard al. Prostate. 2012 Sep 1;72(12):1273-85. doi: 10.1002/pros.22475. Epub 2012 Jan 30. Prostate. 2012. PMID: 22290742

5

Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting.

Rao S, Larroque-Lombard AL, Peyrard L, Thauvin C, Rachid Z, Williams C, Jean-Claude BJ. Rao S, et al. Among authors: larroque lombard al. PLoS One. 2015 Feb 6;10(2):e0117215. doi: 10.1371/journal.pone.0117215. eCollection 2015. PLoS One. 2015. PMID: 25658745 Free PMC article.

6

Biological effects of AL622, a molecule rationally designed to release an EGFR and a c-Src kinase inhibitor.

Larroque-Lombard AL, Ning N, Rao S, Lauwagie S, Halaoui R, Coudray L, Huang Y, Jean-Claude BJ. Larroque-Lombard AL, et al. Chem Biol Drug Des. 2012 Dec;80(6):981-91. doi: 10.1111/cbdd.12043. Chem Biol Drug Des. 2012. PMID: 22943437

7

ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.

Ait-Tihyaty M, Rachid Z, Larroque-Lombard AL, Jean-Claude BJ. Ait-Tihyaty M, et al. Among authors: larroque lombard al. Invest New Drugs. 2013 Dec;31(6):1409-23. doi: 10.1007/s10637-013-0008-y. Invest New Drugs. 2013. PMID: 23959266

8

Quantitative Analysis of the Potency of Equimolar Two-Drug Combinations and Combi-Molecules Involving Kinase Inhibitors In Vitro: The Concept of Balanced Targeting.

Rao S, Thibault B, Peyrard L, Larroque-Lombard AL, Rupp M, Thauvin C, Jean-Claude BJ. Rao S, et al. Among authors: larroque lombard al. Int J Mol Sci. 2021 Sep 3;22(17):9569. doi: 10.3390/ijms22179569. Int J Mol Sci. 2021. PMID: 34502481 Free PMC article.

9

Design and Mechanism of Action of a New Prototype of Combi-Molecule "Programed" to Release Bioactive Species at a pH Range Akin to That of the Tumor Microenvironment.

Larroque-Lombard AL, Chatelut E, Delord JP, Imbs DC, Rochaix P, Jean-Claude B, Allal B. Larroque-Lombard AL, et al. Pharmaceuticals (Basel). 2021 Feb 16;14(2):160. doi: 10.3390/ph14020160. Pharmaceuticals (Basel). 2021. PMID: 33669415 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters